Cargando…

Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis

BACKGOUND: Multiple Sclerosis has two clinical phases reflecting distinct but inter-related pathological processes: focal inflammation drives the relapse-remitting stage and neurodegeneration represents the principal substrate of secondary progression. In contrast to the increasing number of effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hampton, David W, Serio, Andrea, Pryce, Gareth, Al-Izki, Sarah, Franklin, Robin JM, Giovannoni, Gavin, Baker, David, Chandran, Siddharthan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895761/ https://www.ncbi.nlm.nih.gov/pubmed/24364862 http://dx.doi.org/10.1186/2051-5960-1-84

Ejemplares similares

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
por: Hilliard, A., et al.
Publicado: (2012)

Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels
por: Pryce, Gareth, et al.
Publicado: (2023)

Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
por: von Kutzleben, Stephanie, et al.
Publicado: (2017)

Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio
por: York, Elizabeth N., et al.
Publicado: (2022)

Unpicking neurodegeneration in a dish with human pluripotent stem cells: One cell type at a time
por: Bilican, Bilada, et al.
Publicado: (2013)

Systematic review of prediction models in relapsing remitting multiple sclerosis
por: Brown, Fraser S., et al.
Publicado: (2020)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB(2) Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis
por: Sisay, Sofia, et al.
Publicado: (2013)

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
por: Baker, David, et al.
Publicado: (2023)

Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis
por: Warne, Justin, et al.
Publicado: (2016)

Human stem cell-derived astrocytes and their application to studying Nrf2-mediated neuroprotective pathways and therapeutics in neurodegeneration
por: Gupta, Kunal, et al.
Publicado: (2013)

Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
por: Patani, Rickie, et al.
Publicado: (2012)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
por: Bartosik-Psujek, Halina, et al.
Publicado: (2023)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis
por: Licht‐Mayer, Simon, et al.
Publicado: (2022)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Neurodegeneration in multiple sclerosis
por: Mey, Gabrielle M., et al.
Publicado: (2022)

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis
por: Lidster, Katie, et al.
Publicado: (2013)

Deoxyglucose prevents neurodegeneration in culture by eliminating microglia
por: Vilalta, Anna, et al.
Publicado: (2014)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Malaria elimination on Hainan Island despite climate change
por: Tian, Huaiyu, et al.
Publicado: (2022)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Mesenchymal Stem Cells Lack Efficacy in the Treatment of Experimental Autoimmune Neuritis despite In Vitro Inhibition of T-Cell Proliferation
por: Sajic, Marija, et al.
Publicado: (2012)

Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability
por: Devlin, Anna-Claire, et al.
Publicado: (2015)

Rim lesions are demonstrated in early relapsing–remitting multiple sclerosis using 3 T-based susceptibility-weighted imaging in a multi-institutional setting
por: Ng Kee Kwong, Koy Chong, et al.
Publicado: (2021)

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
por: Möhn, Nora, et al.
Publicado: (2020)

Big conductance calcium‐activated potassium channel openers control spasticity without sedation
por: Baker, David, et al.
Publicado: (2017)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Iron and Neurodegeneration in Multiple Sclerosis
por: Khalil, Michael, et al.
Publicado: (2011)

High Yields of Oligodendrocyte Lineage Cells from Human Embryonic Stem Cells at Physiological Oxygen Tensions for Evaluation of Translational Biology
por: Stacpoole, Sybil R.L., et al.
Publicado: (2013)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lkkd8h7fjk3rpplgapluiut556